How does the management of POLE mutated colorectal cancer differ from that of dMMR/MSI high disease?  

Finding a POLE-mutated CRC is like winning the lottery. They have a higher neoantigen load than MSI-H disease and elicit deep responses to immunotherapy. Management should be similar, but the response rate is higher in the metastatic setting [overall response rate (ORR) of 89%, significantly higher ...